61.98
+0.24(+0.39%)
Currency In USD
| Previous Close | 61.74 |
| Open | 60.09 |
| Day High | 62.55 |
| Day Low | 60.05 |
| 52-Week High | 76.61 |
| 52-Week Low | 27.66 |
| Volume | 1.08M |
| Average Volume | 1.39M |
| Market Cap | 8.9B |
| PE | -12.78 |
| EPS | -4.85 |
| Moving Average 50 Days | 51.4 |
| Moving Average 200 Days | 40.77 |
| Change | 0.24 |
If you invested $1000 in Vaxcyte, Inc. (PCVX) since IPO date, it would be worth $2,370.17 as of March 03, 2026 at a share price of $61.98. Whereas If you bought $1000 worth of Vaxcyte, Inc. (PCVX) shares 5 years ago, it would be worth $2,399.54 as of March 03, 2026 at a share price of $61.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
GlobeNewswire Inc.
Feb 11, 2026 9:05 PM GMT
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech